Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myotubularin-related protein 13 (SBF2) is a pseudophosphatase in the myotubularin family encoded by the SBF2 gene in humans. It plays an essential role in cellular signaling, particularly in the maintenance of the myelin sheath surrounding neurons, and in the development of ocular trabecular meshwork. SBF2 acts as a guanine nucleotide exchange factor (GEF) for Rab GTPases. Unlike its active phosphatase relatives, it lacks catalytic activity but is involved in complex protein-protein interactions. Mutations or deficits in SBF2 function result in a demyelinating neuropathy known as Charcot-Marie-Tooth disease type 4B2, manifesting as abnormal myelin structure, and may cause glaucoma when protein function is completely lost. SBF2 gene variants have also been associated with increased susceptibility to taxane-induced peripheral neuropathy in cancer patients[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myotubularin-related protein 13 (SBF2).